GL-0001, a first-in-class dual GIP/GLP-2 analogue, reduces bone fragility by enhancing bone material properties in a murine model of type III osteogenesis imperfecta
Osteogenesis imperfecta (OI) is a severe heritable skeletal disorder characterized by bone fragility, short stature, and increased fracture risk. Currently, no pharmacological treatment has been approved for OI, and bisphosphonates are commonly used off label. While bisphosphonates increase bone mass, their effects on bone quality and fracture reduction remain limited. GL-0001, a first-in-class…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
